Replaces Prod. #: ALX-350-250
Cell permeable and selective inhibitor of the cyclin-dependent kinases CDK1/cyclin B, CDK2 and CDK5. Inhibits cell cycle progression at the G1/S and G2/M transitions. G1/S and G2/M transitions, in W138 cells, were inhibited, concurrent with inhibition of the phosphorylations of, respectively, retinoblastoma protein and histone H1. It is an important tool for probing the cellular roles of CDKs. Blocks Fas-induced apoptosis. Displays antitumor activity.
Product Details
| Formula: | C24H24O7 |
| |
| MW: | 424.5 |
| |
| CAS: | 87414-49-1 |
| |
| Purity: | ≥99% (TLC) |
| |
| Appearance: | White solid. |
| |
| Solubility: | Soluble in 100% ethanol (25mg/ml) or DMSO(>10mg/ml). |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored, as supplied, at -20°C. Stock solutions are stable for up to 3 months at -20°C. |
| |
| Handling: | Protect from light. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Brain sterol flux mediated by cytochrome P450 46A1 affects membrane properties and membrane-dependent processes: A.M. Petrov, et al.; Brain Commun.
2, fcaa043 (2020),
Abstract;
Full Text
Induction of secondary metabolism of Aspergillus terreus ATCC 20542 in the batch bioreactor cultures: T. Boruta, et al.; Appl. Microbiol. Biotechnol.
100, 3009 (2016),
Application(s): Cell culture,
Abstract;
Full Text
Regulation of mitotic function of Chk1 through phosphorylation at novel sites by cyclin-dependent kinase 1 (Cdk1): T. Shiromizu, et al.; Genes Cells
11, 477 (2006),
Abstract;
Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis: H. Lin, et al.; J. Biol. Chem.
279, 29302 (2004),
Abstract;
Full Text
Butyrolactone I reversibly inhibits meiotic maturation of bovine oocytes, without influencing chromosome condensation activity: M. Kubelka, et al.; Biol. Reprod.
62, 292 (2000),
Abstract;
Full Text
Butyrolactone I induces cyclin B1 and causes G2/M arrest and skipping of mitosis in human prostate cell lines: M. Suzuki, et al.; Cancer Lett.
138, 121 (1999),
Abstract;
Effects of cyclin-dependent kinase inhibitors on transcription and ocular circadian rhythm of Aplysia: N. Sankrithi and A. Eskin; J. Neurochem.
72, 605 (1999),
Abstract;
An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells: M. Wada, et al.; Anticancer Res.
18, 2559 (1998),
Abstract;
Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines: K. Nishio, et al.; Anticancer Res.
16, 3387 (1996),
Abstract;
Transcriptional activation of the cdc2 gene is associated with Fas- induced apoptosis of human hematopoietic cells: Y. Furukawa, et al.; J. Biol. Chem.
271, 28469 (1996),
Abstract;
Full Text
Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract: T. Hosoi, et al.; J. Biochem.
117, 741 (1995),
Abstract;
A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression: M. Kitagawa, et al.; Oncogene
9, 2549 (1994),
Abstract;
Inhibition of cell cycle oscillation of DNA replication by a selective inhibitor of the cdc2 kinase family, butyrolactone I, in Xenopus egg extracts: A. Someya, et al.; BBRC
198, 536 (1994),
Abstract;
Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase: M. Kitagawa, et al.; Oncogene
8, 2425 (1993),
Abstract;
